This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
January 25, 2012, 07:00 a.m. ET
Severin Schwan - CEO, Roche Group
Alan Hippe - Chief Financial and IT Officer
Dan O'Day - Diagnostics Division, COO and Member of the Roche Corporate Executive Committee
Sachin Jain - Bank of America/Merrill Lynch
Gbola Amusa - UBS
Bill Quirk - Piper Jaffray
Quintin Lai - Robert W. Baird
Vincent Meunier - Exane BNP Paribas
Alexandra Hauber - JP Morgan
Luisa Hector - Crédit Suisse
Michael Leacock - RBS
Keyur Parekh - Goldman Sachs
Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O’Day, Chief Operating Officer of Roche Diagnostics.
Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today’s success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche.
Over the years, we have developed a number of high-tech platforms, both internally and also as you can see on Page 4, by acquiring a number of key technologies. And we believe that sequencing is and will continue to be an increasingly important technology as we go forward.